• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

安维鲁单抗是一种新型 JAK1 抑制剂，可抑制非小细胞肺癌生长。

Anwulignan is a novel JAK1 inhibitor that suppresses non-small cell lung cancer growth.

机构信息

Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, HA, China.

China-US (Henan) Hormel Cancer Institute, Zhengzhou, HA, China.

出版信息

J Cell Mol Med. 2021 Mar;25(5):2645-2654. doi: 10.1111/jcmm.16289. Epub 2021 Feb 1.

DOI:10.1111/jcmm.16289
PMID:33523587
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7933975/
Abstract

Anwulignan is a monomer compound derived from Schisandra sphenanthera lignans. It has been reported to possess a spectrum of pharmacological activities, including anti-bacterial, anti-inflammatory, anticancer and hepatoprotective properties. However, its anticancer capacity and molecular mechanism(s) against non-small cell lung cancer (NSCLC) have not been fully elucidated. Anwulignan significantly inhibited cell growth and increased G1-phase cell cycle arrest in NSCLC cells. Anwulignan strongly attenuates the JAK1/STAT3 signalling pathway by directly targeting JAK1 protein kinase activity in vitro. The anticancer activity by Anwulignan is dependent upon the JAK1 protein expression. Remarkably, Anwulignan strongly inhibited tumour growth in vivo. In conclusion, Anwulignan is a novel JAK1 inhibitor that may have therapeutic implications for NSCLC management.

摘要

安五灵脂素是一种从五味子木脂素衍生而来的单体化合物。据报道，它具有多种药理活性，包括抗菌、抗炎、抗癌和保肝作用。然而，其抗癌能力及其针对非小细胞肺癌（NSCLC）的分子机制尚不完全清楚。安五灵脂素显著抑制 NSCLC 细胞的生长并增加 G1 期细胞周期阻滞。安五灵脂素通过体外直接靶向 JAK1 蛋白激酶活性，强烈抑制 JAK1/STAT3 信号通路。安五灵脂素的抗癌活性依赖于 JAK1 蛋白的表达。值得注意的是，安五灵脂素强烈抑制体内肿瘤生长。总之，安五灵脂素是一种新型的 JAK1 抑制剂，可能对 NSCLC 的治疗具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c81/7933975/a54e397af9f4/JCMM-25-2645-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c81/7933975/91fbc55fb99f/JCMM-25-2645-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c81/7933975/e02708fbe1f4/JCMM-25-2645-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c81/7933975/0513b5d4f785/JCMM-25-2645-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c81/7933975/b20fdeeb2c83/JCMM-25-2645-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c81/7933975/c7c0f53e36f4/JCMM-25-2645-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c81/7933975/a54e397af9f4/JCMM-25-2645-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c81/7933975/91fbc55fb99f/JCMM-25-2645-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c81/7933975/e02708fbe1f4/JCMM-25-2645-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c81/7933975/0513b5d4f785/JCMM-25-2645-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c81/7933975/b20fdeeb2c83/JCMM-25-2645-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c81/7933975/c7c0f53e36f4/JCMM-25-2645-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c81/7933975/a54e397af9f4/JCMM-25-2645-g006.jpg

相似文献

1
Anwulignan is a novel JAK1 inhibitor that suppresses non-small cell lung cancer growth.安维鲁单抗是一种新型 JAK1 抑制剂，可抑制非小细胞肺癌生长。
J Cell Mol Med. 2021 Mar;25(5):2645-2654. doi: 10.1111/jcmm.16289. Epub 2021 Feb 1.
2
Synthesis, Antiproliferative Activity and Molecular Docking Analysis of Both Enantiomerically Pure Decursin Derivatives as Anticancer Agents.合成、对映体纯升麻素衍生物的抗增殖活性及分子对接分析作为抗癌剂。
Chem Pharm Bull (Tokyo). 2024 May 25;72(5):498-506. doi: 10.1248/cpb.c23-00718. Epub 2024 May 11.
3
Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC.JAK1/2 的抑制作用可以克服人类 NSCLC 中 EGFR-TKI 的耐药性。
Biochem Biophys Res Commun. 2020 Jun 18;527(1):305-310. doi: 10.1016/j.bbrc.2020.04.095. Epub 2020 May 11.
4
Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.IL-6R/JAK1/STAT3 信号的激活导致具有 T790M 耐药突变的非小细胞肺癌对不可逆的 EGFR 抑制剂产生新的耐药性。
Mol Cancer Ther. 2012 Oct;11(10):2254-64. doi: 10.1158/1535-7163.MCT-12-0311. Epub 2012 Aug 13.
5
miR-140-3p inhibits progression of non-small cell lung cancer by targeting Janus kinase 1.miR-140-3p 通过靶向 Janus 激酶 1 抑制非小细胞肺癌的进展。
J Biosci. 2020;45.
6
Rab1A promotes IL-4R/JAK1/STAT6-dependent metastasis and determines JAK1 inhibitor sensitivity in non-small cell lung cancer.Rab1A 促进 IL-4R/JAK1/STAT6 依赖性转移，并决定非小细胞肺癌中 JAK1 抑制剂的敏感性。
Cancer Lett. 2021 Dec 28;523:182-194. doi: 10.1016/j.canlet.2021.10.008. Epub 2021 Oct 8.
7
Berberine suppresses bladder cancer cell proliferation by inhibiting JAK1-STAT3 signaling via upregulation of miR-17-5p.小檗碱通过上调 miR-17-5p 抑制 JAK1-STAT3 信号通路抑制膀胱癌细胞增殖。
Biochem Pharmacol. 2021 Jun;188:114575. doi: 10.1016/j.bcp.2021.114575. Epub 2021 Apr 20.
8
Discovery and synthesis of novel magnolol derivatives with potent anticancer activity in non-small cell lung cancer.发现并合成具有强效抗癌活性的新型厚朴酚衍生物，用于非小细胞肺癌。
Eur J Med Chem. 2018 Aug 5;156:190-205. doi: 10.1016/j.ejmech.2018.06.048. Epub 2018 Jun 27.
9
Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway.氯化两面针碱通过抑制 JAK1/STAT3 信号通路抑制肝癌细胞体内生长。
Int J Mol Med. 2013 Jul;32(1):79-84. doi: 10.3892/ijmm.2013.1358. Epub 2013 Apr 22.
10
JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.JAK激酶抑制可消除STAT3激活以及头颈部鳞状细胞癌肿瘤生长。
Neoplasia. 2015 Mar;17(3):256-64. doi: 10.1016/j.neo.2015.01.003.

引用本文的文献

1
Anwulignan Alleviates Bone Cancer Pain by Modulating the PPARα/CXCR2 Signaling Pathway in the Rat Spinal Cord.安乌利楠通过调节大鼠脊髓中的PPARα/CXCR2信号通路减轻骨癌疼痛。
CNS Neurosci Ther. 2025 Mar;31(3):e70302. doi: 10.1111/cns.70302.
2
Green Seaweed as a Novel Non-Small Cell Lung Cancer Inhibitor in Overcoming Tyrosine Kinase Inhibitor Resistance: An Analysis Employing Network Pharmacology, Molecular Docking, and In Vitro Research.海藻作为一种新型非小细胞肺癌抑制剂，可克服酪氨酸激酶抑制剂耐药性：采用网络药理学、分子对接和体外研究进行分析。
Mar Drugs. 2024 Jun 12;22(6):272. doi: 10.3390/md22060272.
3
A promising natural product in diffuse large B-cell lymphoma therapy by targeting PIM1.

本文引用的文献

1
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.ACVR1/JAK1/JAK2 抑制剂 momelotinib 逆转骨髓纤维化 2 期试验中的输血依赖并抑制铁调素。
Blood Adv. 2020 Sep 22;4(18):4282-4291. doi: 10.1182/bloodadvances.2020002662.
2
Combined inhibition of JAK1/2 and DNMT1 by newly identified small-molecule compounds synergistically suppresses the survival and proliferation of cervical cancer cells.新鉴定的小分子化合物联合抑制 JAK1/2 和 DNMT1 协同抑制宫颈癌细胞的存活和增殖。
Cell Death Dis. 2020 Sep 7;11(9):724. doi: 10.1038/s41419-020-02934-8.
3
靶向 PIM1 的天然产物在弥漫性大 B 细胞淋巴瘤治疗中的应用前景。
Ann Hematol. 2024 Aug;103(8):2905-2915. doi: 10.1007/s00277-024-05670-7. Epub 2024 Mar 1.
4
Identification of Potent and Selective JAK1 Lead Compounds Through Ligand-Based Drug Design Approaches.通过基于配体的药物设计方法鉴定强效和选择性JAK1先导化合物。
Front Pharmacol. 2022 Apr 21;13:837369. doi: 10.3389/fphar.2022.837369. eCollection 2022.
5
Anti-Cancer Effects of α-Cubebenoate Derived from in CT26 Colon Cancer Cells.α-环藤酚酸酯对 CT26 结肠癌细胞的抗癌作用。
Molecules. 2022 Jan 23;27(3):737. doi: 10.3390/molecules27030737.
6
Pharmacological Effects of Polyphenol Phytochemicals on the JAK-STAT Signaling Pathway.多酚类植物化学物质对JAK-STAT信号通路的药理作用。
Front Pharmacol. 2021 Sep 3;12:716672. doi: 10.3389/fphar.2021.716672. eCollection 2021.
Prevention of Tobacco Carcinogen-Induced Lung Tumor Development by a Novel STAT3 Decoy Inhibitor.
新型 STAT3 诱饵抑制剂预防烟草致癌原诱导的肺癌发生。
Cancer Prev Res (Phila). 2020 Sep;13(9):735-746. doi: 10.1158/1940-6207.CAPR-20-0033. Epub 2020 Jul 12.
4
Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC.JAK1/2 的抑制作用可以克服人类 NSCLC 中 EGFR-TKI 的耐药性。
Biochem Biophys Res Commun. 2020 Jun 18;527(1):305-310. doi: 10.1016/j.bbrc.2020.04.095. Epub 2020 May 11.
5
STAT3: Versatile Functions in Non-Small Cell Lung Cancer.信号转导和转录激活因子3（STAT3）：在非小细胞肺癌中的多种功能
Cancers (Basel). 2020 Apr 29;12(5):1107. doi: 10.3390/cancers12051107.
6
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.一项伊曲替尼（一种选择性 JAK1 抑制剂）治疗急性移植物抗宿主病患者的 1 期临床试验。
Blood Adv. 2020 Apr 28;4(8):1656-1669. doi: 10.1182/bloodadvances.2019001043.
7
Discovery of (2)--[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor.（2）--[3-[2-[(3-甲氧基-1-甲基-吡唑-4-基)氨基]嘧啶-4-基]-1-吲哚-7-基]-2-(4-甲基哌嗪-1-基)丙烯酰胺（AZD4205）的发现：一种有效的、选择性的 Janus 激酶 1 抑制剂。
J Med Chem. 2020 May 14;63(9):4517-4527. doi: 10.1021/acs.jmedchem.9b01392. Epub 2020 Apr 28.
8
Inhibition of esophageal-carcinoma cell proliferation by genistein via suppression of JAK1/2-STAT3 and AKT/MDM2/p53 signaling pathways.金雀异黄素通过抑制 JAK1/2-STAT3 和 AKT/MDM2/p53 信号通路抑制食管癌细胞增殖。
Aging (Albany NY). 2020 Apr 10;12(7):6240-6259. doi: 10.18632/aging.103019.
9
Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.分子和细胞对 TYK2/JAK1 抑制剂 PF-06700841 的反应揭示了其对斑块状银屑病皮肤炎症的减轻作用。
J Invest Dermatol. 2020 Aug;140(8):1546-1555.e4. doi: 10.1016/j.jid.2019.11.027. Epub 2020 Jan 21.
10
The IκB Kinase Inhibitor ACHP Targets the STAT3 Signaling Pathway in Human Non-Small Cell Lung Carcinoma Cells.IKK 激酶抑制剂 ACHP 靶向人非小细胞肺癌细胞中的 STAT3 信号通路。
Biomolecules. 2019 Dec 13;9(12):875. doi: 10.3390/biom9120875.